ライフサイエンスコーパス: prolapse

1 omyopathy, cardiac amyloid, and mitral valve prolapse).

2 cal repair of mitral regurgitation caused by prolapse.

3 pse compared with those without pelvic organ prolapse.

4 raphy revealing myxomatous mitral valve with prolapse.

5 med transvaginal surgeries to correct apical prolapse.

6 nually in the United States for pelvic organ prolapse.

7 overgrowth with villous atrophy, and rectal prolapse.

8 air for regurgitation from posterior leaflet prolapse.

9 r cardiac amyloid, and 0.77 for mitral valve prolapse.

10 of mitral regurgitation (MR) in mitral valve prolapse.

11 nt in the pathogenesis of MR in mitral valve prolapse.

12 sociated with significant MR in mitral valve prolapse.

13 nal walls are chronically exposed because of prolapse.

14 epidemiology and prevalence of pelvic organ prolapse.

15 patients at risk for developing pelvic organ prolapse.

16 mesh kits for the treatment of pelvic organ prolapse.

17 n of mitral regurgitant jets in mitral valve prolapse.

18 sional (3D) echocardiography of mitral valve prolapse.

19 weight <2,500 g, maternal age >= 35 and cord prolapse.

20 in the pathogenesis of sporadic mitral valve prolapse.

21 atients with high-grade anterior compartment prolapse.

22 atients with high-grade anterior compartment prolapse.

23 or for defecatory disorders and pelvic organ prolapse.

24 ed the available treatments for pelvic organ prolapse.

25 ave been developed to address apical vaginal prolapse.

26 tive diagnostic criteria, as in mitral valve prolapse.

27 gesting that factors related to aging led to prolapse.

28 95% CI, 2.1%-3.7%) experiencing pelvic organ prolapse.

29 mponents in the pathogenesis of pelvic organ prolapse.

30 compared with Fbln3(-[supi]/-) mice without prolapse.

31 ues from Fbln3(-[supi]/-) mice regardless of prolapse.

32 chments of the vagina, or both, resulting in prolapse.

33 or recovery after reconstructive surgery for prolapse.

34 nsion is commonly performed for uterovaginal prolapse.

35 plicated in the pathogenesis of pelvic organ prolapse.

36 al regurgitation (MR) caused by mitral valve prolapse.

37 referring patients with complex mitral valve prolapse.

38 Stoma prolapse (18, 41.9%) was the most frequent complication

39 ne grafts had complications (23%), including prolapse (26%), ischemia (16%), and parastomal hernia (1

40 aortic valve calcification, and mitral valve prolapse); (3) considerations in replacement and repair

41 chronic moderate and severe OMR (flail 25%, prolapse 75%) defined by using the ECHO-derived integrat

42 lowed for 1.0-7.3 years, 153 (13%) developed prolapse; 754 controls were matched to those women, yiel

43 At baseline, 399 (97%) women had prolapse above or at the level of the hymen.

44 usted OR, 11.25; P = .003), and conjunctival prolapse (adjusted OR, 7.10; P = .03).

45 inence, fecal incontinence, and pelvic organ prolapse) affect many women.

46 Recurrence of apical prolapse after RALS appears to be similar to that in con

47 er some of these anatomic findings may favor prolapse after vaginal birth may be questioned.

48 n), or severe (billowing accompanied by iris prolapse and >/=2 mm of pupil constriction).

49 termine the association between pelvic organ prolapse and exfoliation syndrome in women enrolled in M

50 atched them to 90 patients with mitral valve prolapse and holosystolic MR for age, gender, atrial fib

51 cells recapitulates features of mitral valve prolapse and identified dysregulation of the SHH pathway

52 nefit for symptomatic relief of pelvic organ prolapse and improvement of quality of life.

53 Other complications included prolapse and infections of the graft stoma.

54 rovides unprecedented images of mitral valve prolapse and its associated mitral regurgitation with no

55 ntified MR in 111 patients with mitral valve prolapse and mid-late systolic MR and matched them to 90

56 Intraoperative iris billowing and prolapse and pupil size were recorded and videotaped.

57 Eleven patients with posterior leaflet prolapse and severe MR, with mean+/-SD age of 65+/-13 ye

58 cts, including 36 patients with mitral valve prolapse and significant MR (>/=3+; MR+ group), 32 patie

59 ergoing surgery to treat both apical vaginal prolapse and stress urinary incontinence was conducted b

60 Two years after vaginal surgery for prolapse and stress urinary incontinence, neither ULS no

61 es varied greatly depending on the nature of prolapse and surgical approach.

62 also be effective in secondary prevention of prolapse and the need for future treatment.

63 severe mitral regurgitation, despite larger prolapse and valve redundancy, underscoring potential co

64 rt a strong association between mitral valve prolapse and viridans group streptococcal IE in a popula

65 .4% men) had MV repair for MR due to leaflet prolapse and were followed prospectively for a median of

66 s are classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of coro

67 2 (95% CI, 0.04-0.20) excluding mitral valve prolapse, and 0.44 (95% CI, 0.15-0.73) for >/= moderate

68 of scoliosis, pectus excavatum, mitral valve prolapse, and mutations in the CFTR gene.

69 as observed with regard to blood loss, pain, prolapse, and problems with defecation (P < 0.05).

70 terior capsule tear, intraoperative vitreous prolapse, and use of pupillary expansion devices.

71 aditional procedures for posterior or apical prolapses, and minimal data suggesting anatomic benefit

72 d myopathic repairs by quantifying segmental prolapse, anterior leaflet closing angles, and tenting f

73 Though most mitral valve prolapse are asymptomatic those that cause severe regurg

74 undergoing vaginal surgery for pelvic-organ prolapse are at risk for postoperative urinary incontine

75 Myxomatous mitral valve with prolapse are classically seen with abnormal leaflet appo

76 Women with prolapse are often advised to do pelvic floor muscle exe

77 ession on CT or echocardiogram, mitral valve prolapse, arrhythmia, or restrictive lung disease.

78 ria included anterior leaflet or commissural prolapse, as well as a mixed cause for mitral valve dise

79 e, the pathological hallmark of mitral valve prolapse, associated with symptomatic mitral regurgitati

80 bulge symptoms, and (3) no re-treatment for prolapse at 2 years.

81 that are well accepted in the management of prolapse, because they are minimally invasive and with f

82 composite outcome (re-treatment of prolapse, prolapse beyond the hymen, or prolapse symptoms) was eva

83 agina, or anterior or posterior vaginal wall prolapse beyond the hymen.

84 intraoperative residual MR, anterior leaflet prolapse, bileaflet prolapse, perfusion time >90 min, an

85 +; MR+ group), 32 patients with mitral valve prolapse but no or mild MR (</=2+; MR- group), 12 patien

86 Women of any age who had stage 1-3 prolapse, but had not sought treatment, were randomly as

87 fibulin-5-knockout mice develop pelvic organ prolapse by 20 weeks of age.

88 and the presence or absence of vaginal wall prolapse can all significantly impact on the potential s

89 Surgical strategies for prolapse can be categorised broadly by reconstructive an

90 dures for anterior and posterior compartment prolapse cannot be recommended for primary prolapse repa

91 DM), asthma, allergic rhinitis, mitral valve prolapse, collagen vascular disease, aortic aneurysm, Do

92 ct of PFD, total and by domain (pelvic organ prolapse, colorectal-anal, and urogenital).

93 clinical specimens of sporadic mitral valve prolapse compared with explanted nondiseased mitral valv

94 gnificantly in Fbln3(-[supi]/-) animals with prolapse compared with Fbln3(-[supi]/-) mice without pro

95 ion syndrome risk in women with pelvic organ prolapse compared with those without pelvic organ prolap

96 tely, abdominal mesh repair of vaginal vault prolapse compared with vaginal non-mesh repair.

97 atients, predominantly women, with bileaflet prolapse, complex ventricular ectopy (VE), and abnormal

98 The surgical management of pelvic organ prolapse continues to evolve.

99 Prolapse development is multifactorial, with vaginal chi

100 65 years at baseline who had a pelvic organ prolapse diagnosis compared with controls during 20 year

101 s were prolapse symptom scores (Pelvic Organ Prolapse Distress Inventory; range 0-300, higher scores

102 0005, 95% CI: 3.8-13.5) and the pelvic organ prolapse domain (P = 0.015, 95% CI: 0.6-9.5).

103 standard for evaluation of leaflet flail and prolapse due to high sensitivity and specificity.

104 ch for treatment of uterine or vaginal vault prolapse following hysterectomy.

105 ed from women with uterovaginal pelvic organ prolapse following vaginal hysterectomy.

106 ncluded surgical operations for pelvic organ prolapse for this review.

107 ent of defecatory disorders and pelvic organ prolapse has highlighted the limitations of physical exa

108 dentify women at highest risk for developing prolapse, health-care providers could evaluate not simpl

109 f multiple parameters, such as orifice area, prolapse height and volume in mitral valve disease, area

110 Prolapse height and volume increased little throughout s

111 if they had a third degree or higher uterine prolapse, if they were unable to walk or stand without h

112 included canalicular cheese-wiring and tube prolapse in approximately 4% each.

113 ession, p110delta inactivation led to rectal prolapse in mice resembling autoimmune colitis in patien

114 er, fibulin-5 (FBLN5), leads to pelvic organ prolapse in mice.

115 ry event in the pathogenesis of pelvic organ prolapse in mice.

116 romoting cellular matrix protein, results in prolapse in mice.

117 the pathological progression of mitral valve prolapse in patients.

118 eneration is the most common cause of mitral prolapse in the United States and Europe, and progressio

119 was more frequent in women with pelvic organ prolapse in the Utah Population Database, a robust popul

120 cative information about female pelvic organ prolapse-information that usually can only be inferred b

121 There was a case of a clinically silent coil prolapse into the parent artery.

122 Mitral valve prolapse is a common condition that is a risk factor for

123 Pelvic organ prolapse is a common connective tissue disorder that aff

124 Mitral valve prolapse is a common valvular abnormality but the pathog

125 Pelvic organ prolapse is closely related to SUI, and the genes though

126 Pelvic organ prolapse is common and is strongly associated with child

127 Mitral valve prolapse is defined as abnormal bulging of the mitral va

128 One-to-one pelvic floor muscle training for prolapse is effective for improvement of prolapse sympto

129 When prolapse is symptomatic, options include observation, pe

130 Europe, and progression of myxomatous mitral prolapse is the most common cause of mitral regurgitatio

131 hich leads to spontaneous colitis and rectal prolapse, is associated with alteration of the gut micro

132 y and mesh repairs for anterior vaginal wall prolapse, it is apparent that although mesh repair had s

133 cal trauma is a risk factor for pelvic organ prolapse later in life.

134 rdiography to the ventricular surface of the prolapsed leaflet.

135 wall, suggesting a myocardial stretch by the prolapsing leaflet, is the structural hallmark and corre

136 OI; n = 29; 30%), sarcoidosis (n = 19; 20%), prolapsed LG (n = 15; 15%), lymphoma (n = 11; 11%), lymp

137 DVD for home use (intervention group), or a prolapse lifestyle advice leaflet (control group).

138 ogramme of pelvic floor muscle training or a prolapse lifestyle advice leaflet and no muscle training

139 hmia was associated with male sex, bileaflet prolapse, marked leaflet redundancy, mitral annulus disj

140 involved in the development of pelvic organ prolapse may also be linked to the development of SUI.

141 altered ECM metabolism, such as pelvic organ prolapse, may share common biological pathways with exfo

142 s revealed that the percent of necrotic core prolapse, medial tear, or incomplete apposition was sign

143 m represents the following manifestations: a prolapsed mitral valve, myopia, aortic root enlargement,

144 o investigate the prevalence of mitral valve prolapse (MVP) and its association with ventricular arrh

145 f echocardiographically defined mitral valve prolapse (MVP) in the general population, the actual bur

146 Knowledge of mitral valve prolapse (MVP) inheritance is based on pedigree observat

147 Mitral valve prolapse (MVP) is a common cardiac valve disease that af

148 Nonsyndromic mitral valve prolapse (MVP) is a common degenerative cardiac valvulop

149 Background Mitral valve prolapse (MVP) is a common heart valve disease, the most

150 Although the vast majority of mitral valve prolapse (MVP) is benign, a small subset of patients, pr

151 Arrhythmic mitral valve prolapse (MVP) is characterized by myxomatous leaflets a

152 Mitral valve prolapse (MVP) is often considered benign but recent sug

153 Mitral valve prolapse (MVP) is one of the most common valvular disord

154 Mitral valve prolapse (MVP) may present with ventricular arrhythmias

155 Longitudinal studies of mitral valve prolapse (MVP) progression among unselected individuals

156 mitral valves in patients with mitral valve prolapse (MVP).

157 nclude aortic root dilation and mitral valve prolapse (MVP).

158 ng as controls who did not have pelvic organ prolapse (n = 15338).

159 at baseline with a diagnosis of pelvic organ prolapse (n = 5130) compared with birth year-matched wom

160 Current surgical therapies for prolapse now include augmentation with synthetic mesh, w

161 in 8 eyes (72.7%); lens damage and vitreous prolapse occurred in 2 eyes (18.1%).

162 -)), and overt vaginal, perineal, and rectal prolapse occurred in 26.9% of animals.

163 If significant miosis or iris prolapse occurred, IPH was injected during phacoemulsifi

164 Age, isolated prolapse of the anterior leaflet, the degree of myxomato

165 Prolapse of the conjoined aortic valve cusp toward the l

166 gastrulate, but approximately 90% develop a prolapse of the hindgut by the late prism stage ( approx

167 xcessive mechanical stress and the resulting prolapse of the nucleus pulposus.

168 Dchs1(+/-) mice had prolapse of thickened mitral leaflets, which could be tr

169 oms of stress incontinence and with anterior prolapse (of stage 2 or higher on a Pelvic Organ Prolaps

170 g only), moderate (billowing and either iris prolapse or >/=2 mm of pupil constriction), or severe (b

171 No patient had MV prolapse or flail and 1 had residual moderate-to-severe

172 Significant miosis, iris prolapse, or both occurred in 54.76% of eyes in group 2,

173 a significantly lower rate of the composite prolapse outcome after 3 years.

174 not improve urinary symptoms at 6 months or prolapse outcomes at 2 years.

175 s will help relieve symptomatic mitral valve prolapse patients.

176 assembly in the pathogenesis of pelvic organ prolapse, pelvic organ support was characterized in Fbln

177 ual MR, anterior leaflet prolapse, bileaflet prolapse, perfusion time >90 min, and lack of annuloplas

178 is, membrane-permeable pCPT-cAMP rescues the prolapse phenotype in C5a knockdown embryos, and causes

179 lin-5 gene (Fbln5(-/-)) develop pelvic organ prolapse (POP) due to compromised elastic fibers and upr

180 urinary incontinence (SUI) and pelvic organ prolapse (POP) have produced highly variable outcomes, c

181 Pelvic organ prolapse (POP) is a common condition affecting almost ha

182 Pelvic organ prolapse (POP) is a common, debilitating disorder affect

183 Pelvic organ prolapse (POP) is a disabling disorder in women characte

184 nthetic graft, has been used in pelvic organ prolapse (POP) repair and stress urinary incontinence (S

185 EVIEW: Mesh used for slings and pelvic organ prolapse (POP) repair has resulted in increased efficacy

186 ually adapted new techniques in pelvic organ prolapse (POP) repair in order to improve both anatomic

187 use of commercial mesh kits in pelvic organ prolapse (POP) repair.

188 s more women undergo repairs of pelvic organ prolapse (POP), an ever-increasing scrutiny has been pla

189 oor disorders (PFDs), including pelvic organ prolapse (POP), stress urinary incontinence (SUI), urge

190 omechanical function may induce pelvic organ prolapse (POP).

191 nually in the United States for pelvic organ prolapse (POP).

192 ive surgery in the treatment of pelvic organ prolapse (POP); however, the robotic industry and decrea

193 We examined operatively excised portions of prolapsed posterior mitral leaflets in 37 patients havin

194 raoperative iris trauma, intraoperative iris prolapse, posterior capsular tear, anterior capsule tear

195 Mitral regurgitation (MR) of mitral valve prolapse predominates in late systole but may be holosys

196 ng a first, single incontinence procedure or prolapse procedure during 1997-98 to 2015-16 identified

197 riod, 18 986 women underwent a first, single prolapse procedure, 1279 (7%) of which used mesh.

198 and quality of life after transvaginal mesh prolapse procedures.

199 are clinicopathological features with rectal prolapse, proctitis cystica profunda (PCP) and inflammat

200 t failure composite outcome (re-treatment of prolapse, prolapse beyond the hymen, or prolapse symptom

201 oduction of novel approaches to pelvic organ prolapse provide further options when considering approp

202 ailure requiring retreatment or Pelvic Organ Prolapse Quantification evaluation demonstrating descent

203 apse (of stage 2 or higher on a Pelvic Organ Prolapse Quantification system examination) who were pla

204 Mean prolapse-related quality-of-life scores also did not dif

205 Prolapse-related quality-of-life scores at 2 years were:

206 Score [POP-SS]) and condition-specific (ie, prolapse-related) quality-of-life scores, analysed in th

207 abdominal mesh procedures for vaginal vault prolapse repair are associated with similar effectivenes

208 Long-term outcome data for prolapse repair are rare.

209 le aims to discuss the techniques of robotic prolapse repair as well as morbidity, cost and clinical

210 The use of synthetic materials in prolapse repair demands critical examination, given the

211 nsidered the gold standard for vaginal vault prolapse repair for several decades.

212 s, the use of synthetic materials in vaginal prolapse repair has been increasing despite the lack of

213 of native tissue repair of anterior vaginal prolapse repair in the mesh era.

214 We aimed to compare the outcomes of prolapse repair involving either synthetic mesh inlays o

215 e stress urinary incontinence at the time of prolapse repair is controversial.

216 e of treatment of the urethra at the time of prolapse repair should be discussed with the patient wit

217 durethral sling may be placed at the time of prolapse repair to reduce this risk.

218 and clinical) are post-MUS and pelvic organ prolapse repair urinary retention and obstruction, and u

219 ence interval, 3.7-12.7) for external rectal prolapse repair was noted.

220 preferred approach to abdominal pelvic organ prolapse repair.

221 different vaginal approaches to pelvic organ prolapse repair.

222 nimally invasive techniques for pelvic organ prolapse repair.

223 erlying reason for performing mesh-augmented prolapse repair.

224 t prolapse cannot be recommended for primary prolapse repair.

225 omplications compared with transvaginal mesh prolapse repairs.

226 Regurgitation was related primarily to cusp (prolapse, restriction) and commissure (splaying) morphol

227 ent difference, -6.7; 95% CI, -19.7 to 6.2), prolapse scores at 24 months (adjusted treatment differe

228 , liquid, or mucous stool), and pelvic organ prolapse (seeing/feeling a bulge in or outside the vagin

229 Pelvic floor muscle training can reduce prolapse severity and symptoms in women seeking treatmen

230 Prolapse severity increased with age but not parity.

231 hree or less vs more than three deliveries), prolapse stage (above the hymen vs at or beyond the hyme

232 al size and slope of the GH as a function of prolapse status (case vs. control) and with nested (wome

233 her incontinence (aIRR 3.20 [2.06-4.96]) and prolapse surgery (1.69 [1.29-2.20]); and a substantially

234 aRR] 0.44 [95% CI 0.36-0.55]) and subsequent prolapse surgery (adjusted incidence rate ratio [aIRR] 0

235 ed with a similarly increased risk of repeat prolapse surgery and later complications.

236 ansvaginal anterior or posterior compartment prolapse surgery by 65 gynaecological surgeons in these

237 efining a successful outcome of pelvic organ prolapse surgery from a symptomatic perspective instead

238 RECENT FINDINGS: Success in pelvic organ prolapse surgery has been redefined.

239 aginal mesh and biological graft material in prolapse surgery is controversial and has led to a numbe

240 ic midurethral sling inserted during vaginal prolapse surgery resulted in a lower rate of urinary inc

241 eview of vaginal approaches for pelvic organ prolapse surgery with and without mesh.

242 muscle training (BPMT) improves outcomes of prolapse surgery.

243 fine a successful outcome after pelvic organ prolapse surgery.

244 nation) who were planning to undergo vaginal prolapse surgery.

245 ment protrusion beyond the hymen or reported prolapse surgery.

246 ns, further incontinence surgery, or further prolapse surgery.

247 ts of mesh or graft reinforcement in vaginal prolapse surgery.

248 d controlled trials for our study (PROSPECT [PROlapse Surgery: Pragmatic Evaluation and randomised Co

249 anti-incontinence procedures at the time of prolapse surgery; however, applying these data to midure

250 ted prolapse symptoms (i.e. the Pelvic Organ Prolapse Symptom Score [POP-SS]) and condition-specific

251 cantly greater reduction in the pelvic organ prolapse symptom score [POP-SS]) at 12 months than those

252 elf-reported prolapse symptoms (Pelvic Organ Prolapse Symptom Score [POP-SS]) at 2 years.

253 worse), and primary outcomes at 2 years were prolapse symptom scores (Pelvic Organ Prolapse Distress

254 year and 2 years, were participant-reported prolapse symptoms (i.e. the Pelvic Organ Prolapse Sympto

255 men in the intervention group reported fewer prolapse symptoms (ie, a significantly greater reduction

256 The primary outcome was self-reported prolapse symptoms (Pelvic Organ Prolapse Symptom Score [

257 ry endpoint was participants' self-report of prolapse symptoms at 12 months.

258 t of prolapse, prolapse beyond the hymen, or prolapse symptoms) was evaluated with survival models.

259 for prolapse is effective for improvement of prolapse symptoms.

260 ed pelvic floor muscle training for reducing prolapse symptoms.

261 small, but probably important, reduction in prolapse symptoms.

262 small, but probably important, reduction in prolapse symptoms.

263 p; therefore collectively grouped as mucosal prolapse syndrome.

264 opic ventral mesh rectopexy (LVR) for rectal prolapse syndromes in a large cohort of consecutive pati

265 ective for the treatment of different rectal prolapse syndromes.

266 e likely to present with a posterior leaflet prolapse than those undergoing MV replacement.

267 MR of mitral valve prolapse that is purely mid-late systolic causes more be

268 r the treatment of symptomatic vaginal vault prolapse that is rapidly gaining popularity among both u

269 nt conditions, such as advanced pelvic organ prolapse, that may require referral.

270 ms (rectal bleeding, perianal irritation and prolapse), the best option for treatment depends upon pe

271 n to the excision or repositioning of lax or prolapsed tissues, surgeons must assess and treat facial

272 ere obtained from patients with mitral valve prolapse undergoing mitral valve repair or from organ do

273 Among women with symptomatic uterovaginal prolapse undergoing vaginal surgery, vaginal mesh hyster

274 hiatus (GH) and development of pelvic organ prolapse using data from the Mothers' Outcomes After Del

275 etween exfoliation syndrome and pelvic organ prolapse using the Utah Population Database, a comprehen

276 stress urinary incontinence and pelvic organ prolapse using transvaginal mesh.

277 ials after insertion of IOL and clean of the prolapsed vitreous.

278 were extracted; annulus size, leaflet area, prolapse volume, tethering volume, bending angle, and pa

279 Pelvic organ prolapse was associated with a 1.56-fold increased risk

280 repair, mesh repair of anterior compartment prolapse was associated with a similar risk of immediate

281 repair, mesh repair of posterior compartment prolapse was associated with a similarly increased risk

282 Prolapse was defined as any vaginal segment protrusion b

283 iation of the lens capsule) and pelvic organ prolapse was investigated as part of the Utah Project on

284 g thrombus burden: presence of necrotic core prolapse was more frequent in thrombosed lesions compare

285 e intraoperative miosis, iris billowing, and prolapse was noted during routine phacoemulsification in

286 Prolapse was posterior in 62%, bileaflet in 26%, and ant

287 Mitral valve prolapse was present in 18% (216) of 1215 patients and a

288 Mitral valve prolapse was present in 5.4%, Marfan syndrome in 1.1% an

289 g the use of synthetic mesh for pelvic organ prolapse, we did a retrospective review of the evidence-

290 nt to healthcare providers with pelvic organ prolapse, we need a better understanding of its incidenc

291 %), non-injury wounds (9%), and pelvic organ prolapse were also prevalent.

292 nopausal women with symptomatic uterovaginal prolapse were enrolled in a randomized superiority clini

293 regurgitation (MR) due to isolated posterior prolapse were included in this TACT (Transapical Artific

294 y-diagnosed, symptomatic stage I, II, or III prolapse were randomly assigned (1:1), by remote compute

295 differ significantly (P > 0.05), except for prolapse, which improved more in the non-Doppler group (

296 ble in number by the year 2030, pelvic organ prolapse will become more prevalent.

297 y powered randomized trial, repair of mitral prolapse with either leaflet resection or leaflet preser

298 Treatment of mitral prolapse with regurgitation is complex, and the technolo

299 ntrolled trials evaluating repair of vaginal prolapse with the use of mesh and a paucity of data on l

300 syndrome risk in patients with pelvic organ prolapse (without exfoliation syndrome history) compared